Show simple item record

dc.contributor.authorGrünwald, V
dc.contributor.authorChirovsky, D
dc.contributor.authorCheung, WY
dc.contributor.authorBertolini, F
dc.contributor.authorAhn, M-J
dc.contributor.authorYang, M-H
dc.contributor.authorCastro, G
dc.contributor.authorBerrocal, A
dc.contributor.authorSjoquist, K
dc.contributor.authorKuyas, H
dc.contributor.authorAuclair, V
dc.contributor.authorGuillaume, X
dc.contributor.authorJoo, S
dc.contributor.authorShah, R
dc.contributor.authorHarrington, K
dc.contributor.authorGLANCE H&N STUDY Investigators,
dc.identifier.citationOral oncology, 2020, 102 pp. 104526 - ?
dc.description.abstractOBJECTIVES: Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting. MATERIALS AND METHODS: A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characteristics, treatment and survival data. RESULTS: Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54-67), 84% male, and 70% Eastern Cooperative Oncology Group performance status 0-1; 32% had oral cavity and 30% oropharyngeal cancers. The most common first-line regimen across all countries consisted of platinum-based combinations (73%), including platinum + 5-fluorouracil (5-FU) (26%), cetuximab + platinum ± 5-FU (22%), or taxane + platinum ± 5-FU (16%). However, use of different platinum-based combinations varied substantially; administration of cetuximab + platinum ± 5-FU was frequent in Italy (81%), Germany (46%) and Spain (38%), whereas use in other countries was limited. Median follow-up was 22.6 months (95% confidence interval [CI]: 21.5-24.6 months). Median real-world overall survival was only 8.0 months (95% CI: 7.0-8.0), with one-year survival reaching only 30.9% (95% CI: 27.5-34.3). CONCLUSION: Systemic therapies used in clinical practice for patients with R/M HNSCC vary substantially across countries. Prognosis remains poor in this patient population, highlighting the need for newer, more efficacious treatments.
dc.format.extent104526 - ?
dc.subjectGLANCE H&N STUDY Investigators
dc.titleGlobal treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
dc.typeJournal Article
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOral oncology
pubs.notesNot known
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.embargo.termsNot known
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHarrington, Kevin

Files in this item


This item appears in the following collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as